Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199)
出版年份 2016 全文链接
标题
Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199)
作者
关键词
-
出版物
LEUKEMIA
Volume 31, Issue 9, Pages 1872-1881
出版商
Springer Nature
发表日期
2016-12-26
DOI
10.1038/leu.2016.382
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199
- (2016) K. Bojarczuk et al. BLOOD
- Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma
- (2016) Qingshan Yang et al. CLINICAL CANCER RESEARCH
- Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
- (2016) Stephan Stilgenbauer et al. LANCET ONCOLOGY
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
- (2016) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
- (2015) J. C. Byrd et al. BLOOD
- Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma
- (2015) Q. Yang et al. CLINICAL CANCER RESEARCH
- Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia
- (2015) F. Cervantes-Gomez et al. CLINICAL CANCER RESEARCH
- Increased chronic lymphocytic leukemia proliferation upon IgM stimulation is sustained by the upregulation of miR-132 and miR-212
- (2015) Simona Tavolaro et al. GENES CHROMOSOMES & CANCER
- The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL
- (2015) K Balakrishnan et al. LEUKEMIA
- Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells
- (2014) U. Rozovski et al. BLOOD
- The future of autologous stem cell transplantation in myeloma
- (2014) F. van Rhee et al. BLOOD
- Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK
- (2014) S. Krysov et al. BLOOD
- Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells
- (2014) V. Patel et al. BLOOD
- Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib
- (2014) D. Wodarz et al. BLOOD
- Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 , for relapsed/refractory chronic lymphocytic leukemia
- (2014) J. R. Brown et al. BLOOD
- Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study
- (2014) S E M Herman et al. LEUKEMIA
- PI3K and cancer: lessons, challenges and opportunities
- (2014) David A. Fruman et al. NATURE REVIEWS DRUG DISCOVERY
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Responses and Suppresses Activity in Autoimmune and Inflammatory Disease Models
- (2013) David G. Winkler et al. CHEMISTRY & BIOLOGY
- Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
- (2013) Susan O'Brien et al. LANCET ONCOLOGY
- Impact of bone marrow stromal cells on Bcl-2 family members in chronic lymphocytic leukemia
- (2013) Viralkumar Patel et al. LEUKEMIA & LYMPHOMA
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapies
- (2013) Jan A. Burger et al. SEMINARS IN CANCER BIOLOGY
- Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia
- (2012) M. S. Davids et al. BLOOD
- Lymph node-induced immune tolerance in chronic lymphocytic leukaemia: a role for caveolin-1
- (2012) Christine E. Gilling et al. BRITISH JOURNAL OF HAEMATOLOGY
- Mechanisms and clinical significance of BIM phosphorylation in chronic lymphocytic leukemia
- (2011) A. Paterson et al. BLOOD
- An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737
- (2011) S. Al-harbi et al. BLOOD
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
- (2011) Andrew W. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- The lymph node microenvironment promotes B-cell receptor signaling, NF- B activation, and tumor proliferation in chronic lymphocytic leukemia
- (2010) Y. Herishanu et al. BLOOD
- Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
- (2010) S. E. M. Herman et al. BLOOD
- The role of Bcl-2 family proteins in chronic lymphocytic leukaemia
- (2010) Andrea G.S. Buggins et al. LEUKEMIA RESEARCH
- B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406
- (2009) M. P. Quiroga et al. BLOOD
- MEK/ERK-Mediated Phosphorylation of Bim Is Required to Ensure Survival of T and B Lymphocytes during Mitogenic Stimulation
- (2009) L. A. O'Reilly et al. JOURNAL OF IMMUNOLOGY
- Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles
- (2009) M Plander et al. LEUKEMIA
- Chronic lymphocytic leukaemia: a short overview
- (2008) E. Montserrat et al. ANNALS OF ONCOLOGY
- BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgVH unmutated chronic lymphocytic leukemia (CLL) cells
- (2008) A. Guarini et al. BLOOD
- Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers
- (2008) C. Pepper et al. BLOOD
- High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation
- (2008) J. A. Burger et al. BLOOD
- Direct multiplexed measurement of gene expression with color-coded probe pairs
- (2008) Gary K Geiss et al. NATURE BIOTECHNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started